Guardant Health Inc.

NASDAQ: GH · Real-Time Price · USD
46.89
-1.98 (-4.05%)
At close: May 02, 2025, 3:59 PM
46.85
-0.09%
After-hours: May 02, 2025, 05:34 PM EDT
-4.05%
Bid 45.52
Market Cap 5.79B
Revenue (ttm) 774M
Net Income (ttm) -416.55M
EPS (ttm) -3.39
PE Ratio (ttm) -13.83
Forward PE -19.71
Analyst Buy
Ask 48.75
Volume 4,280,282
Avg. Volume (20D) 2,232,374
Open 50.20
Previous Close 48.87
Day's Range 45.52 - 51.38
52-Week Range 18.01 - 52.92
Beta 1.45

About GH

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test fo...

Sector Healthcare
IPO Date Oct 4, 2018
Employees 1,999
Stock Exchange NASDAQ
Ticker Symbol GH
Full Company Profile

Analyst Forecast

According to 21 analyst ratings, the average rating for GH stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 17.30% from the latest price.

Stock Forecasts

Earnings Surprise

Guardant Health has released their quartely earnings on Apr 30, 2025:
  • Revenue of $203.47M exceeds estimates by $13.47M, with 20.76% YoY growth.
  • EPS of -0.49 exceeds estimates by 0.10, with -6.52% YoY decline.
  • 3 days ago
    +3.47%
    Guardant Health shares are trading higher after th... Unlock content with Pro Subscription
    2 days ago
    -4.64%
    Guardant Health shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance.